FOR IMMEDIATE RELEASE
Results of ISS wireless, left-atrium, implantable, hemodynamic monitor and LVADs will be presented at the ISHLT 35th Annual Meeting in Nice, France (April 15-18, 2015).
Michigan, USA, March 31, 2015: Integrated Sensing Systems, Inc. (ISS) announced today that further results of implantation of an LVAD (Left Ventricle Assist Device) together with its miniature, wireless, left-atrium, implantable, hemodynamic monitor (IHM) will be presented at the International Society for Heart and Lung Transplantation Conference, ISHLT 35th Annual Meeting and Scientific Sessions on April 15-18, 2015 in Nice, France.
The presentation, entitled “Change of Left Atrial Pressure, LAP Measured with a Wireless Implantable Pressure Sensor (Titan Sensor) During Echocardiographic RAMP-Test in HeartMate II™ Patients,” will be presented by Doctor Laila Hubbert (Linkoping University, Linkoping, Sweden). The abstract can be found on the following web site:
ISS wireless IHM implant distinguishes itself by being able to monitor the left side of the heart (both left atrium and left ventricle). There are 2 on-going clinical studies in Europe with ISS left-heart wireless IHM: 1) monitoring left-heart hemodynamics to improve the long-term treatment of congestive heart failure patients, and 2) monitoring left atrium to improve safety and treatment of LVAD patients. The ISHLT presentation discusses the results from the LAVD clinical study.
Being able to wirelessly monitor the left atrium in hospital settings or at home provides invaluable on-demand information for the early detection of potentially-dangerous conditions such as LVAD-thrombosis. It also helps with intelligent adjustments of LVAD settings. A custom-made internet database allows the patients to submit the home-monitored cardiac pressure waveforms to a database which is immediately accessible to medical staff anywhere in the world. Unlike using pulmonary artery pressures for monitoring left heart failure, directly using left atrium pressure has the advantage of not being adversely affected by common pulmonary comorbidities such as pulmonary embolism.
Dr. Nader Najafi, ISS President and CEO, stated that, “the early results are very promising and may lead to the use of ISS IHM implants as the standard of care for LVADs. In fact, ISS wireless implant by providing information of a sudden LA-pressure rise in an LVAD patient raised a strong suspicion of LVAD thrombosis when the patient was completely asymptomatic and the echocardiogram was negative. The LVAD thrombosis was confirmed by subsequent intraoperative observation which resulted in exchanging the LVAD filled with thrombi.”
Company Background: ISS is a leader in advanced MEMS technologies for design and manufacturing of industrial, medical, microfluidic and scientific analytical sensing applications. Founded in 1995, ISS is one of the oldest independent MEMS companies in the US. ISS operates a comprehensive, state-of-the-art MEMS fabrication facility located near Ann Arbor, Michigan. ISS is currently certified for ISO 9001:2008, EN13980:2002 for its ATEX (intrinsically safe products), and ISO13485:2003 standard for Class III medical devices. ISS is a vertically integrated company dedicated to developing and manufacturing system-level products based on MEMS technology (MEMS Inside), please visit: http://www.mems-issys.com/
Source: Integrated Sensing Systems, Inc. (ISS)
Contact: Nader Najafi, Ph.D.
Integrated Sensing Systems Inc. (ISS)
391 Airport Industrial Dr., Ypsilanti, MI 48198
Tel: (734) 547-9896 Ext. 103
Fax: (734) 547-9964